Puma Biotechnology develops and sells cancer treatments, including the breast cancer drug NERLYNX. It last closed at $7.14 on Nov 17, down 2.72% on the day.
PBYI · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, oversold
The stock is 33% below its 20 day and 35% below its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the swing low (Jun 16) at $6.96, and the nearest resistance the Pivot R1 at $7.36.
Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 7.2%/day
Key levels
$11.5052 week high+61.1%
$9.6650 day average+35.3%
$9.5320 day average+33.5%
$9.11100 day average+27.6%
$8.04200 day average+12.6%
$7.45Swing high (May 27)+4.3%
$7.36Pivot R1+3.1%
$7.14Pivot+0.0%
$7.14Last close
$6.96Swing low (Jun 16)−2.5%
$6.92Pivot S1−3.1%
$4.8052 week low−32.8%
Indicators
RSI (14)
24.09
Oversold below 30
Oversold
MACD
-0.71
Below its signal line
Bearish
Stochastic
4.2
Near the bottom of its range
Oversold
ADX (14)
31.2
Trending down
Williams %R
-94.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-123.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−30.1%
Change over 10 sessions
Bearish
ATR (14)
$0.52
Typical daily range, 7.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 14.3%/day
Key levels
$11.5052 week high+61.1%
$9.6650 day average+35.3%
$9.5320 day average+33.5%
$9.11100 day average+27.6%
$8.04200 day average+12.6%
$7.45Swing high (May 27)+4.3%
$7.36Pivot R1+3.1%
$7.14Pivot+0.0%
$7.14Last close
$6.96Swing low (Jun 16)−2.5%
$6.92Pivot S1−3.1%
$4.8052 week low−32.8%
Indicators
RSI (14)
40.29
Middle of its range
Neutral
MACD
0.30
Below its signal line
Bearish
Stochastic
9.9
Near the bottom of its range
Oversold
ADX (14)
46.8
Strong downtrend
Williams %R
-95.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-157.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−21.7%
Change over 10 sessions
Bearish
ATR (14)
$1.02
Typical daily range, 14.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200–
What happened before, for PBYI
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PBYI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow PBYI usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PBYI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PBYI is in one of them and how their past PBYI trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company based in Los Angeles, California, that develops and sells cancer treatments. Its main commercial product is NERLYNX, an oral form of neratinib approved in the United States for certain types of HER2 positive breast cancer. In the United States the company markets NERLYNX through its own sales force, and it works with partners in other countries to sell the drug there. It is also developing alisertib, an investigational cancer drug aimed at small cell lung cancer and hormone receptor positive breast cancer.